Trial Profile
Phase I/II Trial to Establish the Safety and Preliminary Efficacy of the Combination of Docetaxel, Prednisone, and SOM 230 (Pasireotide) in Metastatic Castrate Resistant Prostate Cancer (CRPC).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 02 Mar 2021 Status changed from active, no longer recruiting to completed.
- 02 Dec 2016 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017.
- 02 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Mar 2017.